A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen's disease: A therapeutic challenge

Journal of Dermatological Treatment

Volumn 17, Issue 3, 2006, Pages 179-183

  Baskan, Emel Bulbul ^a   Tunali, Sukran ^a   Adim, Saduman Balaban ^a   Turan, Aysegul ^a   Toker, Semra ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Bowen's disease; Epidermodysplasia verruciformis; Imiquimod; Interferon alpha; Squamous cell carcinoma

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; ARTICLE; BOWEN DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; EPIDERMODYSPLASIA VERRUCIFORMIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION SENSITIVITY; MALE; PHYLOGENY; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; SYMPTOM; VIRUS INFECTION; WART VIRUS;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EPIDERMODYSPLASIA VERRUCIFORMIS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; SCALP; SKIN NEOPLASMS;

EID: 33746608141     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600788844     Document Type: Article

References (26)

1. Lowy DR, Androphy EJ. Warts. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SJ, et al., editors, Fitzpatrick's dermatology in general medicine. 5th ed. Vol. 2. New York: McGraw-Hill, 1999. p. 2484-97.
2. Gubinelli E, Posteraro P, Cocurccia B, Girolomoni G. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatol Treat. 2003;14:184-8.
3. Nuovo GJ, Ishag M. The histologic spectrum of epidermodysplasia verruciformis. Am J Surg Pathol. 2000;24:1400-6.
4. Iraji F, Faghihi G. Epidermodysplasia verruciformis: association with isolated IgM deficiency and response to treatment with acitretin. Clin Exp Dermatol. 2000;25:41-3.
5. Barzegar C, Paul C, Saiag P, Cassenot P, Bachelez H, Autran B, et al. Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. Br J Dermatol. 1998;139:122-7.
6. Hu W, Nuovo G, Willen M, Somach S. Epidermodysplasia verruciformis in two half brothers with HIV infection. J Cutan Med Surg. 2004;8:357-60.
7. Orth G. Epidermodysplasia verruciformis: A model for understanding the oncogenicity of human papillomaviruses. Ciba Found Symp. 1986;120:157-74.
8. Ostrow RS, Manias D, Mitchell AJ, Stawowy L, Faras AJ. Epidermodysplasia verruciformis. A case associated with primary lymphatic dysplasia, depressed cell-mediated immunity, and Bowen's disease containing human papillomavirus 16 DNA. Arch Dermatol. 1987;123:1511-16.
9. Pfister H. Human papillomaviruses and impaired immunity vs epidermodysplasia verruciformis. Arch Dermatol. 1987;123:1469-70.
10. Adachi A, Kiyono T, Hayashi Y, Ohashi M, Ishibashi M. Detection of human papillomavirus (HPV) type 47 DNA in malignant lesions from epidermodysplasia verruciformis by protocols for precise typing of related HPV DNAs. J Clin Microbiol. 1996;34:369-75.
11. Ishiji T, Kawase M, Honda M, Niimura M, Yoshimura E, Sata T, et al. Distinctive distribution of human papillomavirus type 16 and type 20 DNA in the tonsillar and the skin carcinomas of a patient with epidermodysplasia verruciformis. Br J Dermatol. 2000;143:1005-10.
12. Stadler R, Mayer-da-Silva A, Bratzke B, Garbe C, Orfanos C. Interferons in dermatology. J Am Acad Dermatol. 1989;20:650-6.
13. Tanaka N, Sato M, Lamphier MS, Nozawa H, Oda E, Noguchi S, et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells. 1998;3:29-37.
14. Anadolu R, Oskay T, Erdem C, Boyvat A. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol. 2001;45:296-9.
15. Nimura M. Application of beta-interferon in virus-induced papillomas. J Invest Dermatol. 1990;95:132-7.
16. Gaspari AA, Zalka AD, Payne D, Meregus M, Bunce LA, Abboud LN, et al. Successful treatment of a generalized human papillomavirus infection with granulocyte-macrophage colony-stimulating factor and interferon gamma immunotherapy in a patient with a primary immunodeficiency and cyclic neutropenia. Arch Dermatol. 1997;133:491-6.
17. Kim KY, Blatt L, Taylor MW. The effects of interferon on the expression of human papillomavirus oncogenes. J Gen Virol. 2000;81:695-700.
18. Somani N, Rivers JK. Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett. 2005;10(2), 1-6.
19. Eklind J, Tartler U, Maschke J, Lidbrink P, Hengge UR. Imiquimod to treat different cancers of the epidermis. Dermatol Surg. 2003;29:890-6.
20. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27:561-4.
21. Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg. 2001;27:143-6.
22. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44:462-70.
23. Stanley MA. Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571-7.
24. Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J. 2004;10:4.
25. Skinner RB Jr. Imiquimod. Dermatol Clin. 2003;21:291-300.
26. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-49.